Loss of Response to Anti-TNFs: Definition, Epidemiology, and Management

Tumor necrosis factor-α (TNFα) antagonists have advanced the management of inflammatory bowel diseases patients leading to an improvement of patient's quality of life with the reduction of number of surgeries and hospitalizations. Despite these advances, many patients do not respond to the indu...

Descripción completa

Detalles Bibliográficos
Autores principales: Roda, Giulia, Jharap, Bindia, Neeraj, Narula, Colombel, Jean-Frederic
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Clinical/Narrative Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4737871/
https://www.ncbi.nlm.nih.gov/pubmed/26741065
http://dx.doi.org/10.1038/ctg.2015.63
Descripción
Sumario:Tumor necrosis factor-α (TNFα) antagonists have advanced the management of inflammatory bowel diseases patients leading to an improvement of patient's quality of life with the reduction of number of surgeries and hospitalizations. Despite these advances, many patients do not respond to the induction therapy (primary non-response—PNR) or lose response during the treatment (secondary loss of response—LOR). In this paper we will provide an overview of the definition, epidemiology and risk factors for PNR and LOR, as well as discuss the therapeutic options for managing LOR.

Ejemplares similares